Ventas Inkomsten in het verleden
Verleden criteriumcontroles 4/6
Ventas heeft de winst zien groeien met een gemiddeld jaarlijks percentage van 24.9%, terwijl de Health Care REITs-industrie de winst zag groeien met 17.3% per jaar. De inkomsten zijn gegroeid met een gemiddeld jaarlijks percentage van 9.6%. Het rendement op eigen vermogen van Ventas is 2%, en het heeft een nettomarge van 4.3%.
Belangrijke informatie
24.87%
Groei van de winst
20.42%
Groei van de winst per aandeel
| Health Care REITs Groei van de industrie | -12.20% |
| Inkomstengroei | 9.64% |
| Rendement op eigen vermogen | 2.01% |
| Nettomarge | 4.26% |
| Laatste winstupdate | 31 Mar 2026 |
Recente prestatie-updates uit het verleden
Recent updates
Seeking Alpha • Apr 28
Ventas: Senior Housing Growth Appears Priced In
Summary Ventas (VTR) has marginally outperformed U.S. REIT peers in 2026, building on the strong returns achieved in 2025. This comes as VTR reported solid Q1 2026 results and lifted its full-year outlook, citing higher occupancy in senior housing and increased investment volumes. With occupancy for the U.S. portfolio already increasing in 2024-2026, the end of outsized normalized FFO growth, partially driven by occupancy gains, may come in the next few years. VTR's net operating income outside senior housing only grew 2% Y/Y, in line with long-term inflation and most REIT peers. The company is conservatively funding portfolio growth with share issuance, reducing risks in the near term, but potentially resulting in a drag on returns in the long term. Read the full article on Seeking Alpha
Narratiefupdate • Apr 24
VTR: Higher Dividend And Earnings Outlook Will Support Bullish Cash Flow Trajectory
Analysts have adjusted their price target on Ventas slightly higher to $93.10 from $92.95, reflecting updated views on fair value, discount rate, profit margin, and future P/E assumptions. What's in the News Company issued full year 2026 earnings guidance, projecting net income attributable to common stockholders of US$260 million to US$310 million, or US$0.52 to US$0.62 per share (Company guidance) Board of Directors declared a quarterly cash dividend of US$0.52 per share, described as an 8% increase, payable on April 16, 2026 to stockholders of record on March 31, 2026 (Company announcement) Management linked the dividend decision to expectations for cash flow growth and a positive outlook, which indicates how they are currently thinking about capital returns to shareholders (Company announcement) Valuation Changes Fair Value: Price target moved slightly to $93.10 from $92.95, a small upward adjustment.Narratiefupdate • Apr 08
VTR: Higher Dividend And Earnings Outlook Will Support Bullish Future P/E
Analysts have adjusted their fair value estimate for Ventas slightly higher to $92.95 from $92.50. This reflects updated views on the discount rate, revenue growth, profit margin, and expected future P/E levels.Narratiefupdate • Mar 25
VTR: 2026 Dividend Increase And Earnings Guidance Will Support Bullish P/E Outlook
Analysts now place Ventas' fair value at $92.50, up from $90.90. This reflects updated assumptions around discount rates, revenue growth, profit margins and future P/E levels.Narratiefupdate • Mar 10
VTR: 2026 Earnings Outlook And Dividend Increase Will Support Balanced P/E Expectations
Analysts have nudged their price target on Ventas up by about $1, reflecting slightly adjusted fair value, discount rate, and forward P/E assumptions in their models. What's in the News Ventas issued full year 2026 earnings guidance, projecting net income attributable to common stockholders in a range of $260m to $310m, or $0.52 to $0.62 per share (company guidance).Narratiefupdate • Feb 24
VTR: 2026 Earnings Guidance And Dividend Policy Will Support P/E Upside
Analysts have increased their price target on Ventas from $87.75 to $89.50. The change reflects small adjustments to their model assumptions regarding the discount rate, revenue growth, profit margin and future P/E expectations.Narratiefupdate • Feb 09
VTR: Steady Fair Value And 2026 Guidance Will Support P/E Upside
Analysts have lifted their price target on Ventas from $85.65 to $87.75, citing updated assumptions that combine slightly lower revenue growth with higher expected profit margins, a reduced discount rate, and a lower future P/E multiple. What's in the News Board of Directors declared a quarterly dividend of $0.52 per share, which the company describes as an 8% increase.Narratiefupdate • Jan 26
VTR: Steady Fair Value And Higher 2025 Guidance Will Support P/E Upside
Analysts have kept their fair value estimate for Ventas steady at US$85.65, with only marginal tweaks to inputs such as the discount rate, profit margin and forward P/E assumptions that guide the updated price target rationale. What's in the News Ventas updated its full-year 2025 earnings guidance, with attributable net income per share now expected in a range of US$0.49 to US$0.52, compared with the prior range of US$0.47 to US$0.52 (Key Developments).Narratiefupdate • Jan 12
VTR: Raised 2025 Earnings Guidance Will Support Attractive Forward P/E Upside
Analysts now set their fair value estimate for Ventas at $85.65, up slightly from $85.15. This reflects small adjustments to assumptions for the discount rate, revenue growth, profit margin, and forward P/E ratio.Narratiefupdate • Dec 27
VTR: Full Year 2025 Guidance Will Support Steady Earnings Outlook
Analysts have modestly raised their price target on Ventas to approximately 85.15 dollars from 84.70 dollars, reflecting slightly lower discount rate assumptions and a marginally higher long term valuation multiple. What's in the News Raised full year 2025 earnings guidance, increasing expected attributable net income per share to a range of 0.49 to 0.52 dollars from the prior 0.47 to 0.52 dollars (company guidance) Valuation Changes Fair Value: risen slightly from 84.70 dollars to 85.15 dollars per share, reflecting a modest upward adjustment in intrinsic valuation.Narratiefupdate • Dec 13
VTR: Full Year 2025 Guidance Will Support Improved Profitability Outlook
Analysts have modestly raised their price target on Ventas from 82.95 dollars to 84.70 dollars, citing slightly faster anticipated revenue growth, marginally improved profit margins, and a lower discount rate that together support a higher future earnings multiple. What's in the News Ventas raised its full year 2025 earnings guidance, now expecting attributable net income per share of 0.49 to 0.52 dollars, up from the prior range of 0.47 to 0.52 dollars (company guidance) Valuation Changes Fair Value Estimate has risen slightly to 84.70 dollars from 82.95 dollars, reflecting a modestly higher intrinsic valuation.Narratiefupdate • Nov 29
VTR: Full Year 2025 Guidance Will Drive Improved Profitability Outlook
Analysts have raised their price target for Ventas from $79.90 to $82.95, citing stronger revenue growth and improved profit margin projections as key factors supporting the upward revision. What's in the News Ventas, Inc.Narratiefupdate • Nov 15
VTR: Full Year 2025 Guidance Update Will Support Balanced Valuation Outlook
Analysts have revised their price target for Ventas upward from $78.25 to $79.90. They cite slight improvements in fair value estimates and lower discount rates as reasons for the adjustment.Narratiefupdate • Nov 01
VTR: Future Expansion And Stable Income Will Balance Sector Opportunities And Risks
Analysts have raised their price target for Ventas from $77.39 to $78.25. This reflects increased optimism about the company’s revenue growth prospects and modest adjustments in profitability expectations.Narratiefupdate • Aug 27
Increasing Aging Demand Will Reshape Senior Housing And Medical Offices
Ventas’s consensus analyst price target saw a marginal increase to $77.28, with minimal changes in both future P/E and net profit margin, indicating little shift in the company’s underlying valuation metrics. What's in the News Ventas raised its 2025 earnings guidance, now expecting attributable net income per share of $0.47–$0.52, compared to the prior range of $0.43–$0.53.Seeking Alpha • Apr 08
Why Ventas Is Poised For Strong Long-Term Returns
Summary Ventas is a well-run REIT that's experiencing high growth, particularly in its SHOP portfolio. It carries a strong balance sheet and management has resumed meaningful dividend growth. The recent dip in price has brought the yield to 3%. Combined with high single digit FFO/share growth, VTR could deliver potential market-beating total returns. Read the full article on Seeking AlphaSeeking Alpha • Nov 10
Ventas: Growth Set To Continue In The Years Ahead
Summary Ventas is a healthcare REIT focused on senior housing, outpatient medical & research, and triple-net lease properties. The Q3 2024 results were solid and the company increased its normalized FFO midpoint outlook. With a valuation above private market alternatives and distressed peers, Ventas is tapping debt and equity markets to grow its portfolio and increase normalized FFO. Senior housing should continue to drive net operating income growth as occupancy in the US portfolio keeps rising. Key risks to consider include a potential increase in senior housing supply in the coming years, as well as Ventas's premium enterprise-level valuation. Read the full article on Seeking AlphaSeeking Alpha • Aug 25
Ventas: Net Operating Income Growth Concentrated In Senior Housing
Summary Ventas is a healthcare REIT focused on Senior Housing, Outpatient Medical & Research, and Net Lease properties, primarily in the United States. The REIT has outperformed the Vanguard Real Estate Index Fund ETF in 2024 with a 22% total return. While Q2 2024 results were excellent and the company increased its guidance, I think the normalized FFO multiple and market-implied cap rate are quite elevated. I propose complementing your long stock position with covered calls. Key risks to consider include growth concentrated in senior housing, low gearing following the recent stock rally, and little floating rate debt, limiting benefits from Fed rate cuts. Read the full article on Seeking AlphaSeeking Alpha • Jun 10
Ventas: 4 Reasons To Be Cautious As Bulls Try And Sell Demographic Boom 2.0
Summary "Silver Tsunami" refers to the aging baby boomer generation. Ventas, Inc. has been benefitting from this in the last 12 months and expects to benefit over the next 5 as well. We give you our Debbie Downer take with 4 reasons to be cautious. Read the full article on Seeking AlphaOpbrengsten en kosten
Opbrengsten en kosten
Hoe Ventas geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 26 | 6,113 | 260 | 187 | 0 |
| 31 Dec 25 | 5,817 | 251 | 177 | 0 |
| 30 Sep 25 | 5,544 | 238 | 178 | 0 |
| 30 Jun 25 | 5,275 | 191 | 173 | 0 |
| 31 Mar 25 | 5,056 | 142 | 167 | 0 |
| 31 Dec 24 | 4,889 | 81 | 163 | 0 |
| 30 Sep 24 | 4,764 | -67 | 158 | 0 |
| 30 Jun 24 | 4,673 | -157 | 156 | 0 |
| 31 Mar 24 | 4,581 | -73 | 153 | 0 |
| 31 Dec 23 | 4,500 | -41 | 149 | 0 |
| 30 Sep 23 | 4,359 | 5 | 146 | 0 |
| 30 Jun 23 | 4,256 | 77 | 148 | 0 |
| 31 Mar 23 | 4,173 | -69 | 147 | 0 |
| 31 Dec 22 | 4,154 | -47 | 145 | 0 |
| 30 Sep 22 | 4,079 | -43 | 140 | 0 |
| 30 Jun 22 | 4,019 | 16 | 135 | 0 |
| 31 Mar 22 | 3,921 | 145 | 132 | 0 |
| 31 Dec 21 | 3,818 | 49 | 130 | 0 |
| 30 Sep 21 | 3,760 | 200 | 131 | 0 |
| 30 Jun 21 | 3,701 | 152 | 133 | 0 |
| 31 Mar 21 | 3,703 | -91 | 130 | 0 |
| 31 Dec 20 | 3,790 | 439 | 130 | 0 |
| 30 Sep 20 | 3,847 | 340 | 135 | 0 |
| 30 Jun 20 | 3,911 | 413 | 143 | 0 |
| 31 Mar 20 | 3,925 | 780 | 158 | 0 |
| 31 Dec 19 | 3,859 | 433 | 159 | 0 |
| 30 Sep 19 | 3,781 | 484 | 163 | 0 |
| 30 Jun 19 | 3,720 | 501 | 162 | 0 |
| 31 Mar 19 | 3,714 | 457 | 156 | 0 |
| 31 Dec 18 | 3,702 | 409 | 146 | 0 |
| 30 Sep 18 | 3,668 | 740 | 148 | 0 |
| 30 Jun 18 | 3,646 | 1,252 | 142 | 0 |
| 31 Mar 18 | 3,607 | 1,237 | 139 | 0 |
| 31 Dec 17 | 3,568 | 1,357 | 135 | 0 |
| 30 Sep 17 | 3,560 | 1,172 | 132 | 0 |
| 30 Jun 17 | 3,527 | 707 | 130 | 0 |
| 31 Mar 17 | 3,481 | 699 | 129 | 0 |
| 31 Dec 16 | 3,447 | 650 | 127 | 0 |
| 30 Sep 16 | 3,410 | 569 | 123 | 0 |
| 30 Jun 16 | 3,369 | 465 | 124 | 0 |
| 31 Mar 16 | 3,331 | 453 | 125 | 0 |
| 31 Dec 15 | 3,284 | 407 | 128 | 0 |
| 30 Sep 15 | 3,171 | 366 | 129 | 0 |
| 30 Jun 15 | 3,049 | 412 | 126 | 0 |
Kwaliteitswinsten: VTR heeft een grote eenmalige verlies van $66.2M wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 31st March, 2026.
Groeiende winstmarge: De huidige netto winstmarges (4.3%) VTR } zijn hoger dan vorig jaar (2.8%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: VTR is de afgelopen 5 jaar winstgevend geworden en heeft de winst met 24.9% per jaar laten groeien.
Versnelling van de groei: De winstgroei van VTR over het afgelopen jaar ( 83% ) overtreft het 5-jarig gemiddelde ( 24.9% per jaar).
Winst versus industrie: De winstgroei VTR over het afgelopen jaar ( 83% ) overtrof de Health Care REITs -sector 20.5%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 2% ) van VTR wordt als laag beschouwd.
Rendement op activa
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/22 19:50 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Ventas, Inc. wordt gevolgd door 41 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jacob Kilstein | Argus Research Company |
| David Rodgers | Baird |
| Amanda Sweitzer | Baird |